CELU: Celularity Inc Price to Sales
The success of Celularity Inc. (CELU) is based on the efficacy of placental cells in treating inflammation. High competition in regenerative medicine and pressure from traditional therapy methods influence the price-to-sales ratio dynamics on the current GURU.Markets platform chart, where 1.10 reflects the latest metric value. Business stability is further supported by flawless biomaterial logistics that adhere to all temperature requirements.
Celularity Inc. (CELU) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- business earnings and investment ratios data:
CELU - Net Profit|Company Profit Forecast Celularity Inc.|CELU - Price to Earnings Ratio|Market Cap to Future Earnings Ratio celularity.com|CELU - Price/Earnings to Growth Multiple|Company Value to EBITDA Celularity Corp|CELU - Operating profit before deduction of amortization|Earnings per share for the trailing year Celularity|CELU - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months celularity.com|CELU - Earnings per share growth in current year|Projected earnings per share growth rate for next year Celularity Inc.
- issuer revenue and sales details:
Fundamental company analysis:Celularity Inc CELU
Fundamental asset screening begins by filtering market noise through dynamic metrics. This market cap-to-revenue ratio compares the total value of Celularity Inc. (CELU) with its sales volume, determining the premium paid per unit of revenue. Analyzing this indicator allows for an assessment of market expectations regarding the scaling of the allogeneic cell therapy platform. For Celularity Inc. (CELU), such a valuation is critical during its expansion into the oncology and immunopharmaceuticals segments.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Protagonist Corp (PTGX) - Market Cap to Revenue|IMVT: P/S Multiple|Price to Sales kiniksa.com (KNSA)|Price-to-Revenue Ratio Grifols|Price-to-Revenue Ratio ADPT|Market Cap to Revenue CLDX (Celldex)|P/S Multiple Aurinia Corp (AUPH)|Price-to-Revenue Ratio BioCryst BCRX|veratx.com - Price-to-Revenue Ratio|Dianthus Therapeutics, Inc. - P/S Multiple|PHVS - P/S Multiple|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Tourmaline - Market Capitalization-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|pharming.com (PHAR) - Price-to-Revenue Coefficient|Market Cap to Revenue NKTR (Nektar Therapeutics Inc.)|Market Cap to Sales Volume UPB|Zenas Biopharma, Inc. - Market Cap to Revenue|Immunome Bio (IMNM) - Price to Sales|GOSS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio KALV (kalvista.com)|SEPN: P/S Multiple|PVLA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Savara Corp|Market Cap to Revenue Ratio RIGL (Rigel Corp)|P/S Multiple ANAB|Market Cap to Revenue astriatx.com ATXS|enGene - Market Cap to Revenue|Price-to-Revenue Coefficient RAPT Therapeutics Inc. (RAPT)|Aerovate - P/S Multiple|Aclaris Therapeutics, Inc (ACRS) - Market Cap to Revenue|KYTX: P/S Multiple|Price to Sales tizianalifesciences.com (TLSA)|Price-to-Revenue Ratio Cabaletta Bio|Price-to-Revenue Ratio VTYX|Market Cap to Revenue THTX (Theratechnologies Inc)|P/S Multiple Avalo Therapeutics Inc (AVTX)|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|AGEN (agenusbio.com) - Price-to-Sales Ratio|Climb Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio ZURA (Zura Bio Ltd)|ATYR: P/S Multiple|Adagene Inc. (ADAG) - P/S Multiple|Price-to-Revenue Ratio ImageneBio|STTK: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Equillium, Inc. (EQ)|Market Cap to Revenue connectbiopharm.com CNTB|P/S Multiple IMUX (Immunic)|P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio XFOR (x4pharma.com)|ACET: P/S Multiple|INMB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Kezar Life Sciences Inc (KZR)|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|Market Cap to Revenue akaritx.com AKTX|Enlivex Therapeutics Ltd. - Market Cap to Revenue|P/S Multiple Q32 Bio Inc QTTB|GOVX - Price-to-Revenue Ratio|EDSA (Edesa Biotech Corp) - Market Cap to Revenue Ratio|IBIO: P/S Multiple|Price to Sales Carisma Therapeutics Inc. (CARM)|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Market Cap to Revenue Bolt Bio (BOLT)|P/S Multiple HCWB|APVO - Price to Sales|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|Aditxt Inc. - Price-to-Revenue Ratio|GRI: Market Cap to Revenue|XRTX - P/S Multiple|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|REVB (Revelation Biosciences Corp) - Price-to-Revenue Ratio|INDP (Indaptus Therapeutics) - P/S Multiple|P/S Multiple scinai.com|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|AFMD (affimed.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos)|Price-to-Revenue Coefficient HOOKIPA Pharma, Inc. (HOOK)|IGMS: Market Cap to Revenue|iteostherapeutics.com - Market Cap to Sales Volume|OCEA (Ocean Biomedical) - Market Cap to Revenue|Price to Sales TC BioPharm (Holdings) Plc (TCBP)|Market Cap to Revenue THRD
